Items where authors include "Mateos, M-V"

Article

Ludwig, H L, Terpos, E, van de Donk, N et al. (26 more authors) (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. The Lancet Oncology, 24 (6). e255-e269. ISSN 1470-2045

D'Agostino, M, Cairns, DA orcid.org/0000-0002-2338-0179, Lahuerta, JJ et al. (28 more authors) (2022) Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 40 (29). pp. 3406-3420. ISSN 0732-183X

Thanarajasingam, G, Minasian, LM, Bhatnagar, V et al. (37 more authors) (2022) Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet Haematology, 9 (5). e374-e384. ISSN 2352-3026

San-Miguel, JF, Avet-Loiseau, H, Paiva, B et al. (24 more authors) (2022) Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE. Blood, 139 (4). pp. 492-501. ISSN 0006-4971

Ludwig, H, Sonneveld, P, Facon, T et al. (33 more authors) (2021) COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. The Lancet Haematology, 8 (12). e934-e946. ISSN 2352-3026

Cook, G orcid.org/0000-0001-7196-7364, Corso, A, Streetly, M et al. (11 more authors) (2021) Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. Oncology and Therapy, 9. pp. 139-151. ISSN 2366-1070

Weisel, K, Mateos, M-V, Gay, F et al. (6 more authors) (2021) Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia, 35 (6). pp. 1732-1744. ISSN 0887-6924

Terpos, E, Mikhael, J, Hajek, R et al. (13 more authors) (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 11 (2). 40. ISSN 2044-5385

Dimopoulos, MA, Moreau, P, Terpos, E et al. (14 more authors) (2021) Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 5 (2). e528. ISSN 2572-9241

Chari, A, Samur, MK, Martinez-Lopez, J et al. (22 more authors) (2020) Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood, 136 (26). pp. 3033-3040. ISSN 0006-4971

Terpos, E, Engelhardt, M, Cook, G orcid.org/0000-0001-7196-7364 et al. (15 more authors) (2020) Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 34. pp. 2000-2011. ISSN 0887-6924

Mateos, M-V, Spencer, A, Nooka, AK et al. (16 more authors) (2019) Daratumumab-Based Regimens Are Highly Effective And Well Tolerated In Relapsed Or Refractory Multiple Myeloma Regardless Of Patient Age: Subgroup Analysis Of The Phase 3 CASTOR And POLLUX Studies. Haematologica. ISSN 0390-6078

Dimopoulos, MA, Gay, F, Schjesvold, F et al. (24 more authors) (2019) Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 393 (10168). pp. 253-264. ISSN 0140-6736

Thanarajasingam, G, Minasian, LM, Baron, F et al. (37 more authors) (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet Haematology, 5 (11). e563-e598. ISSN 2352-3026

Gay, F, Jackson, G, Rosiñol, L et al. (28 more authors) (2018) Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. JAMA Oncology, 4 (10). pp. 1389-1397. ISSN 2374-2437

Ludwig, H, Delforge, M, Facon, T et al. (29 more authors) (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 32 (7). pp. 1542-1560. ISSN 0887-6924

Cook, G, Zweegman, S, Mateos, M-V et al. (2 more authors) (2018) A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Critical Reviews in Oncology/Hematology, 121. pp. 74-89. ISSN 1040-8428

Moreau, P, van de Donk, NWCJ, San Miguel, J et al. (17 more authors) (2016) Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016). Drugs, 76 (9). pp. 989-990. ISSN 0012-6667

Proceedings Paper

Weisel, K, Mateos, M-V, Gay, FM et al. (6 more authors) (2018) Association between Patient Profile and Outcomes of Best Responders to Carfilzomib: A Post-Hoc Sub-Group Analysis of Aspire and Endeavor. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology , p. 3299.